Drugs / 3,4-methylenedioxymethamphetamine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06189027 Comparator | Nov 2018 → Nov 2023 | post-traumatic stress disorder | University of Southern California | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3,4-methylenedioxymethamphetamine | “A recent Phase 3 clinical trial reported high efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for treating patients with severe PTSD compared to a therapy...” PMID 36815187 ↗ Feb 2023 |
| Known as | MDMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06189027 ↗ |